Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C

M. S. Soloway, A. Perry

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Thirty patients with stage Ta carcinoma in situ of T1 superficial bladder cancer received 6 weeks of intravesical bacillus Calmette-Guerin. All patients had persistent or recurrent tumor despite thiotepa and/or mitomycin C. Response was determined by the results of endoscopy, bladder wash cytology and biopsy performed 4 weeks after the last dose of bacillus Calmette-Guerin. Of the 30 patients 15 (50 per cent) had a complete response. The likelihood of a complete response was better for those with initial Ta lesions (62 per cent) and carcinoma in situ (56 per cent) than for patients with an initial T1 lesion (25 per cent). Although the longest followup is only 36 months (mean 16 months) patients with a complete response have a much better prognosis in terms of subsequent tumor, need for cystectomy and death of bladder cancer.

Original languageEnglish
Pages (from-to)871-873
Number of pages3
JournalJournal of Urology
Volume137
Issue number5
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Thiotepa
Transitional Cell Carcinoma
Mitomycin
Mycobacterium bovis
Urinary Bladder
Carcinoma in Situ
Urinary Bladder Neoplasms
Therapeutics
Cystectomy
Endoscopy
Cell Biology
Neoplasms
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C. / Soloway, M. S.; Perry, A.

In: Journal of Urology, Vol. 137, No. 5, 01.01.1987, p. 871-873.

Research output: Contribution to journalArticle

@article{f30fc1c33cd04224a5b418a3fa4ebba7,
title = "Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C",
abstract = "Thirty patients with stage Ta carcinoma in situ of T1 superficial bladder cancer received 6 weeks of intravesical bacillus Calmette-Guerin. All patients had persistent or recurrent tumor despite thiotepa and/or mitomycin C. Response was determined by the results of endoscopy, bladder wash cytology and biopsy performed 4 weeks after the last dose of bacillus Calmette-Guerin. Of the 30 patients 15 (50 per cent) had a complete response. The likelihood of a complete response was better for those with initial Ta lesions (62 per cent) and carcinoma in situ (56 per cent) than for patients with an initial T1 lesion (25 per cent). Although the longest followup is only 36 months (mean 16 months) patients with a complete response have a much better prognosis in terms of subsequent tumor, need for cystectomy and death of bladder cancer.",
author = "Soloway, {M. S.} and A. Perry",
year = "1987",
month = "1",
day = "1",
language = "English",
volume = "137",
pages = "871--873",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C

AU - Soloway, M. S.

AU - Perry, A.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Thirty patients with stage Ta carcinoma in situ of T1 superficial bladder cancer received 6 weeks of intravesical bacillus Calmette-Guerin. All patients had persistent or recurrent tumor despite thiotepa and/or mitomycin C. Response was determined by the results of endoscopy, bladder wash cytology and biopsy performed 4 weeks after the last dose of bacillus Calmette-Guerin. Of the 30 patients 15 (50 per cent) had a complete response. The likelihood of a complete response was better for those with initial Ta lesions (62 per cent) and carcinoma in situ (56 per cent) than for patients with an initial T1 lesion (25 per cent). Although the longest followup is only 36 months (mean 16 months) patients with a complete response have a much better prognosis in terms of subsequent tumor, need for cystectomy and death of bladder cancer.

AB - Thirty patients with stage Ta carcinoma in situ of T1 superficial bladder cancer received 6 weeks of intravesical bacillus Calmette-Guerin. All patients had persistent or recurrent tumor despite thiotepa and/or mitomycin C. Response was determined by the results of endoscopy, bladder wash cytology and biopsy performed 4 weeks after the last dose of bacillus Calmette-Guerin. Of the 30 patients 15 (50 per cent) had a complete response. The likelihood of a complete response was better for those with initial Ta lesions (62 per cent) and carcinoma in situ (56 per cent) than for patients with an initial T1 lesion (25 per cent). Although the longest followup is only 36 months (mean 16 months) patients with a complete response have a much better prognosis in terms of subsequent tumor, need for cystectomy and death of bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023277740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023277740&partnerID=8YFLogxK

M3 - Article

C2 - 3106653

AN - SCOPUS:0023277740

VL - 137

SP - 871

EP - 873

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -